An Open, Multi-center Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
Latest Information Update: 04 May 2026
At a glance
- Drugs BL-0020 (Primary) ; Toripalimab (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors Shanghai Best-Link Biosciences
Most Recent Events
- 04 May 2026 New trial record